Trans-activation, post-transcriptional maturation, and induction of antibodies to HERV-K (HML-2) envelope transmembrane protein in HIV-1 infection

Henri Alexandre Michaud, Miguel de Mulder, Devi SenGupta, Steven G. Deeks, Jeffrey N. Martin, Christopher D. Pilcher, Frederick M. Hecht, Jonah Sacha, Douglas F. Nixon

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Background: Human Endogenous Retroviruses (HERVs) comprise about 8% of the human genome and have lost their ability to replicate or to produce infectious particles after having accumulated mutations over time. We assessed the kinetics of expression of HERV-K (HML-2) Envelope mRNA transcript and surface unit (SU) and transmembrane (TM) subunit proteins during HIV-1 infection. We also mapped the specificity of the humoral response to HERV-K (HML-2) Envelope protein in HIV-1 infected subjects at different stages of disease, and correlated the response with plasma viral load.Results: We found that HIV-1 modified HERV-K (HML-2) Env mRNA expression, resulting in the expression of a fully N-glycosylated HERV-K (HML-2) envelope protein on the cell surface. Serological mapping of HERV-K (HML-2) envelope protein linear epitopes revealed two major immunogenic domains, one on SU and another on the ectodomain of TM. The titers of HERV-K (HML-2) TM antibodies were dramatically increased in HIV-1 infected subjects (p <0.0001). HIV-1 infected adults who control HIV-1 in the absence of therapy (" elite" controllers) had a higher titer response against TM compared to antiretroviral-treated adults (p <0.0001) and uninfected adults (p <0.0001).Conclusions: These data collectively suggest that HIV-1 infection induces fully glycosylated HERV-K (HML-2) envelope TM protein to which antibodies are induced. These anti-HERV-K (HML-2) TM antibodies are a potential marker of HIV-1 infection, and are at higher titer in elite controllers. HERV-K (HML-2) envelope TM protein may be a new therapeutic target in HIV-1 infection.

Original languageEnglish (US)
Article number10
JournalRetrovirology
Volume11
Issue number1
DOIs
StatePublished - Jan 28 2014

Fingerprint

Endogenous Retroviruses
Transcriptional Activation
HIV Infections
HIV-1
Antibodies
Proteins
Messenger RNA
Protein Subunits
Human Genome
Viral Load
Epitopes
Membrane Proteins

Keywords

  • Alternative transcripts
  • Antibody
  • Elite controllers
  • Endogenous retroviruses
  • Envelope
  • HERV
  • HIV
  • Transmembrane

ASJC Scopus subject areas

  • Virology
  • Infectious Diseases

Cite this

Michaud, H. A., de Mulder, M., SenGupta, D., Deeks, S. G., Martin, J. N., Pilcher, C. D., ... Nixon, D. F. (2014). Trans-activation, post-transcriptional maturation, and induction of antibodies to HERV-K (HML-2) envelope transmembrane protein in HIV-1 infection. Retrovirology, 11(1), [10]. https://doi.org/10.1186/1742-4690-11-10

Trans-activation, post-transcriptional maturation, and induction of antibodies to HERV-K (HML-2) envelope transmembrane protein in HIV-1 infection. / Michaud, Henri Alexandre; de Mulder, Miguel; SenGupta, Devi; Deeks, Steven G.; Martin, Jeffrey N.; Pilcher, Christopher D.; Hecht, Frederick M.; Sacha, Jonah; Nixon, Douglas F.

In: Retrovirology, Vol. 11, No. 1, 10, 28.01.2014.

Research output: Contribution to journalArticle

Michaud, Henri Alexandre ; de Mulder, Miguel ; SenGupta, Devi ; Deeks, Steven G. ; Martin, Jeffrey N. ; Pilcher, Christopher D. ; Hecht, Frederick M. ; Sacha, Jonah ; Nixon, Douglas F. / Trans-activation, post-transcriptional maturation, and induction of antibodies to HERV-K (HML-2) envelope transmembrane protein in HIV-1 infection. In: Retrovirology. 2014 ; Vol. 11, No. 1.
@article{e9b2adb5d7df447cab7d8f7570294e31,
title = "Trans-activation, post-transcriptional maturation, and induction of antibodies to HERV-K (HML-2) envelope transmembrane protein in HIV-1 infection",
abstract = "Background: Human Endogenous Retroviruses (HERVs) comprise about 8{\%} of the human genome and have lost their ability to replicate or to produce infectious particles after having accumulated mutations over time. We assessed the kinetics of expression of HERV-K (HML-2) Envelope mRNA transcript and surface unit (SU) and transmembrane (TM) subunit proteins during HIV-1 infection. We also mapped the specificity of the humoral response to HERV-K (HML-2) Envelope protein in HIV-1 infected subjects at different stages of disease, and correlated the response with plasma viral load.Results: We found that HIV-1 modified HERV-K (HML-2) Env mRNA expression, resulting in the expression of a fully N-glycosylated HERV-K (HML-2) envelope protein on the cell surface. Serological mapping of HERV-K (HML-2) envelope protein linear epitopes revealed two major immunogenic domains, one on SU and another on the ectodomain of TM. The titers of HERV-K (HML-2) TM antibodies were dramatically increased in HIV-1 infected subjects (p <0.0001). HIV-1 infected adults who control HIV-1 in the absence of therapy ({"} elite{"} controllers) had a higher titer response against TM compared to antiretroviral-treated adults (p <0.0001) and uninfected adults (p <0.0001).Conclusions: These data collectively suggest that HIV-1 infection induces fully glycosylated HERV-K (HML-2) envelope TM protein to which antibodies are induced. These anti-HERV-K (HML-2) TM antibodies are a potential marker of HIV-1 infection, and are at higher titer in elite controllers. HERV-K (HML-2) envelope TM protein may be a new therapeutic target in HIV-1 infection.",
keywords = "Alternative transcripts, Antibody, Elite controllers, Endogenous retroviruses, Envelope, HERV, HIV, Transmembrane",
author = "Michaud, {Henri Alexandre} and {de Mulder}, Miguel and Devi SenGupta and Deeks, {Steven G.} and Martin, {Jeffrey N.} and Pilcher, {Christopher D.} and Hecht, {Frederick M.} and Jonah Sacha and Nixon, {Douglas F.}",
year = "2014",
month = "1",
day = "28",
doi = "10.1186/1742-4690-11-10",
language = "English (US)",
volume = "11",
journal = "Retrovirology",
issn = "1742-4690",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Trans-activation, post-transcriptional maturation, and induction of antibodies to HERV-K (HML-2) envelope transmembrane protein in HIV-1 infection

AU - Michaud, Henri Alexandre

AU - de Mulder, Miguel

AU - SenGupta, Devi

AU - Deeks, Steven G.

AU - Martin, Jeffrey N.

AU - Pilcher, Christopher D.

AU - Hecht, Frederick M.

AU - Sacha, Jonah

AU - Nixon, Douglas F.

PY - 2014/1/28

Y1 - 2014/1/28

N2 - Background: Human Endogenous Retroviruses (HERVs) comprise about 8% of the human genome and have lost their ability to replicate or to produce infectious particles after having accumulated mutations over time. We assessed the kinetics of expression of HERV-K (HML-2) Envelope mRNA transcript and surface unit (SU) and transmembrane (TM) subunit proteins during HIV-1 infection. We also mapped the specificity of the humoral response to HERV-K (HML-2) Envelope protein in HIV-1 infected subjects at different stages of disease, and correlated the response with plasma viral load.Results: We found that HIV-1 modified HERV-K (HML-2) Env mRNA expression, resulting in the expression of a fully N-glycosylated HERV-K (HML-2) envelope protein on the cell surface. Serological mapping of HERV-K (HML-2) envelope protein linear epitopes revealed two major immunogenic domains, one on SU and another on the ectodomain of TM. The titers of HERV-K (HML-2) TM antibodies were dramatically increased in HIV-1 infected subjects (p <0.0001). HIV-1 infected adults who control HIV-1 in the absence of therapy (" elite" controllers) had a higher titer response against TM compared to antiretroviral-treated adults (p <0.0001) and uninfected adults (p <0.0001).Conclusions: These data collectively suggest that HIV-1 infection induces fully glycosylated HERV-K (HML-2) envelope TM protein to which antibodies are induced. These anti-HERV-K (HML-2) TM antibodies are a potential marker of HIV-1 infection, and are at higher titer in elite controllers. HERV-K (HML-2) envelope TM protein may be a new therapeutic target in HIV-1 infection.

AB - Background: Human Endogenous Retroviruses (HERVs) comprise about 8% of the human genome and have lost their ability to replicate or to produce infectious particles after having accumulated mutations over time. We assessed the kinetics of expression of HERV-K (HML-2) Envelope mRNA transcript and surface unit (SU) and transmembrane (TM) subunit proteins during HIV-1 infection. We also mapped the specificity of the humoral response to HERV-K (HML-2) Envelope protein in HIV-1 infected subjects at different stages of disease, and correlated the response with plasma viral load.Results: We found that HIV-1 modified HERV-K (HML-2) Env mRNA expression, resulting in the expression of a fully N-glycosylated HERV-K (HML-2) envelope protein on the cell surface. Serological mapping of HERV-K (HML-2) envelope protein linear epitopes revealed two major immunogenic domains, one on SU and another on the ectodomain of TM. The titers of HERV-K (HML-2) TM antibodies were dramatically increased in HIV-1 infected subjects (p <0.0001). HIV-1 infected adults who control HIV-1 in the absence of therapy (" elite" controllers) had a higher titer response against TM compared to antiretroviral-treated adults (p <0.0001) and uninfected adults (p <0.0001).Conclusions: These data collectively suggest that HIV-1 infection induces fully glycosylated HERV-K (HML-2) envelope TM protein to which antibodies are induced. These anti-HERV-K (HML-2) TM antibodies are a potential marker of HIV-1 infection, and are at higher titer in elite controllers. HERV-K (HML-2) envelope TM protein may be a new therapeutic target in HIV-1 infection.

KW - Alternative transcripts

KW - Antibody

KW - Elite controllers

KW - Endogenous retroviruses

KW - Envelope

KW - HERV

KW - HIV

KW - Transmembrane

UR - http://www.scopus.com/inward/record.url?scp=84893416710&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893416710&partnerID=8YFLogxK

U2 - 10.1186/1742-4690-11-10

DO - 10.1186/1742-4690-11-10

M3 - Article

VL - 11

JO - Retrovirology

JF - Retrovirology

SN - 1742-4690

IS - 1

M1 - 10

ER -